Your browser doesn't support javascript.
loading
The Combination of the M2 Muscarinic Receptor Agonist and Chemotherapy Affects Drug Resistance in Neuroblastoma Cells.
Lucianò, Anna Maria; Perciballi, Elisa; Fiore, Mario; Del Bufalo, Donatella; Tata, Ada Maria.
Affiliation
  • Lucianò AM; Department of Biology and Biotechnologies Charles Darwin, Sapienza University of Rome, 00185 Rome, Italy.
  • Perciballi E; Department of Biology and Biotechnologies Charles Darwin, Sapienza University of Rome, 00185 Rome, Italy.
  • Fiore M; Institute of Molecular Biology and Pathology, CNR, 00185 Rome, Italy.
  • Del Bufalo D; Preclinical Models and New Therapeutic Agents Unit, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy.
  • Tata AM; Department of Biology and Biotechnologies Charles Darwin, Sapienza University of Rome, 00185 Rome, Italy.
Int J Mol Sci ; 21(22)2020 Nov 10.
Article in En | MEDLINE | ID: mdl-33182656
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Arecoline / Antineoplastic Combined Chemotherapy Protocols / Receptor, Muscarinic M2 / Neuroblastoma Limits: Humans Language: En Journal: Int J Mol Sci Year: 2020 Document type: Article Affiliation country:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Arecoline / Antineoplastic Combined Chemotherapy Protocols / Receptor, Muscarinic M2 / Neuroblastoma Limits: Humans Language: En Journal: Int J Mol Sci Year: 2020 Document type: Article Affiliation country: